Spots Global Cancer Trial Database for erbitux
Every month we try and update this database with for erbitux cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment | NCT01134640 | Metastatic Colo... | - | Merck KGaA, Darmstadt, Germany | ||
| Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas | NCT05745857 | Barrett's Esoph... Barrett Oesopha... Esophageal Aden... | Avastin Erbitux Fluorescence en... | 18 Years - | University Medical Center Groningen | |
| Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver | NCT00766220 | Colon Cancer Colorectal Canc... | SIR-spheres Age... Cetuximab Irinotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) | NCT01102231 | Stage III Non-s... | Chemotherapy ERBITUX Radiotherapy | 18 Years - 70 Years | Intergroupe Francophone de Cancerologie Thoracique | |
| A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma | NCT03254927 | Advanced Head a... | CDX-3379 and ce... | 18 Years - | Celldex Therapeutics | |
| Sirolimus and Cetuximab in Advanced Malignancies | NCT00940381 | Advanced Cancer | Sirolimus Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Combination With Cetuximab | NCT00895362 | Advanced Cancer... | Erlotinib Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Regorafenib and Cetuximab in Patients With Advanced Malignancy | NCT02095054 | Advanced Cancer... | Regorafenib Cetuximab Questionnaire | 12 Years - | M.D. Anderson Cancer Center | |
| A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer | NCT01032291 | Colorectal Canc... | cetuximab lenalidomide | 18 Years - | Celgene | |
| A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN) | NCT01080066 | Carcinoma, Squa... | No Intervention | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer | NCT01790516 | Head and Neck S... | Cisplatin cetuximab Radiation | 18 Years - | Georgetown University | |
| Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma | NCT00725400 | Colorectal Carc... | Cetuximab and R... Surgery and Rad... | 40 Years - | American Scitech International | |
| HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver | NCT00980239 | Liver Cancer Advanced Cancer | Irinotecan Bevacizumab Oxaliplatin Cetuximab | - | M.D. Anderson Cancer Center | |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib | NCT01432119 | Advanced Cancer... | SIR-Spheres Cetuximab Erlotinib Break-Through S... | 18 Years - | M.D. Anderson Cancer Center | |
| An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment | NCT01074333 | Colorectal Neop... | Cetuximab | - | Merck KGaA, Darmstadt, Germany | |
| Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix | NCT00518193 | Cervix Cancer | ERBITUX | 18 Years - | ARCAGY/ GINECO GROUP | |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib | NCT01432119 | Advanced Cancer... | SIR-Spheres Cetuximab Erlotinib Break-Through S... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab | NCT00319839 | Head and Neck C... | Abraxane Cetuximab | 18 Years - | University of California, Irvine | |
| FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer | NCT00501410 | Colorectal Canc... | 5-FU Cetuximab Dasatinib Leucovorin Oxaliplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck | NCT00617734 | Head and Neck C... | IMC-A12 (cixutu... cetuximab (Erbi... | 18 Years - | Eli Lilly and Company | |
| Erlotinib in Combination With Cetuximab | NCT00895362 | Advanced Cancer... | Erlotinib Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma | NCT01794845 | Squamous Cell C... Head and Neck C... Recurrent Disea... | Erbitux Taxotere Low Dose Fracti... | - | University of Miami | |
| An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | NCT01142869 | Carcinoma, Squa... | Cetuximab | - | Merck KGaA, Darmstadt, Germany | |
| HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver | NCT00980239 | Liver Cancer Advanced Cancer | Irinotecan Bevacizumab Oxaliplatin Cetuximab | - | M.D. Anderson Cancer Center | |
| Phase 1 and 2 Study of PX-866 and Cetuximab | NCT01252628 | Incurable Metas... Incurable Progr... | PX-866 (SCCHN) Cetuximab (SCCH... PX-866 (CRC) Cetuximab (CRC) | 18 Years - | Seagen Inc. | |
| Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas | NCT05745857 | Barrett's Esoph... Barrett Oesopha... Esophageal Aden... | Avastin Erbitux Fluorescence en... | 18 Years - | University Medical Center Groningen | |
| Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients | NCT02239731 | Rash Due to Epi... | FDX104 (4% Doxy... | 18 Years - | Vyne Therapeutics Inc. | |
| An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer | NCT01134666 | Colorectal Neop... | Cetuximab | - | Merck KGaA, Darmstadt, Germany | |
| Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT01427205 | Head and Neck C... | Cetuximab OSI-906 Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy | NCT03769506 | Head and Neck C... | ASP-1929 Photoi... Physician's Cho... | 18 Years - | Rakuten Medical, Inc. | |
| Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients | NCT00338039 | Pancreatic Canc... | Cetuximab Gemcitabine Oxaliplatin Capecitabine Radiotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer | NCT04474470 | Solid Tumor, Ad... Squamous Cell C... Colorectal Aden... Metastatic Soli... Recurrent Solid... Head and Neck C... | NT219 NT219 and ERBIT... NT219 and ERBIT... | 18 Years - | Purple Biotech Ltd. | |
| Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients | NCT00338039 | Pancreatic Canc... | Cetuximab Gemcitabine Oxaliplatin Capecitabine Radiotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| Sirolimus and Cetuximab in Advanced Malignancies | NCT00940381 | Advanced Cancer | Sirolimus Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor | NCT00660582 | Metastatic Colo... | Cetuximab (Erbi... Oxaliplatin (El... | 18 Years - 75 Years | Odense University Hospital | |
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment | NCT01134640 | Metastatic Colo... | - | Merck KGaA, Darmstadt, Germany | ||
| An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment | NCT01074333 | Colorectal Neop... | Cetuximab | - | Merck KGaA, Darmstadt, Germany | |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer | NCT04590963 | Squamous Cell C... | Monalizumab Cetuximab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Reirradiation and Erbitux in the HNSCC | NCT01237483 | Head and Neck C... | Erbitux | 18 Years - 75 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck | NCT00617734 | Head and Neck C... | IMC-A12 (cixutu... cetuximab (Erbi... | 18 Years - | Eli Lilly and Company | |
| Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab | NCT00941499 | Advanced Cancer... | HAI Oxaliplatin 5-FU Bevacizumab Cetuximab Leucovorin 5-FU Bevacizumab | - | M.D. Anderson Cancer Center | |
| Sirolimus and Cetuximab in Advanced Malignancies | NCT00940381 | Advanced Cancer | Sirolimus Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer | NCT00681876 | Colorectal Canc... | Irinotecan Avastin Erbitux | 18 Years - 72 Years | Hellenic Oncology Research Group | |
| ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy | NCT03769506 | Head and Neck C... | ASP-1929 Photoi... Physician's Cho... | 18 Years - | Rakuten Medical, Inc. | |
| Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab | NCT00319839 | Head and Neck C... | Abraxane Cetuximab | 18 Years - | University of California, Irvine | |
| A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice | NCT01460745 | Metastatic Colo... | 18 Years - | Merck KGaA, Darmstadt, Germany | ||
| Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab | NCT00319839 | Head and Neck C... | Abraxane Cetuximab | 18 Years - | University of California, Irvine | |
| A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer | NCT04474470 | Solid Tumor, Ad... Squamous Cell C... Colorectal Aden... Metastatic Soli... Recurrent Solid... Head and Neck C... | NT219 NT219 and ERBIT... NT219 and ERBIT... | 18 Years - | Purple Biotech Ltd. | |
| Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma | NCT00353457 | Rectal Cancer | Capecitabine, O... Radiation | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Phase 1 and 2 Study of PX-866 and Cetuximab | NCT01252628 | Incurable Metas... Incurable Progr... | PX-866 (SCCHN) Cetuximab (SCCH... PX-866 (CRC) Cetuximab (CRC) | 18 Years - | Seagen Inc. | |
| A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment | NCT01082315 | Colorectal Neop... | Erbitux (Cetuxi... | - | Merck KGaA, Darmstadt, Germany | |
| A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver | NCT00803647 | Metastatic Colo... | cetuximab 5-FU oxaliplatin leucovorin | 18 Years - | NSABP Foundation Inc | |
| Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) | NCT04515394 | Colorectal Neop... | Tepotinib Cetuximab | 18 Years - | EMD Serono | |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer | NCT04590963 | Squamous Cell C... | Monalizumab Cetuximab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients | NCT00338039 | Pancreatic Canc... | Cetuximab Gemcitabine Oxaliplatin Capecitabine Radiotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab | NCT00941499 | Advanced Cancer... | HAI Oxaliplatin 5-FU Bevacizumab Cetuximab Leucovorin 5-FU Bevacizumab | - | M.D. Anderson Cancer Center | |
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment | NCT01134640 | Metastatic Colo... | - | Merck KGaA, Darmstadt, Germany | ||
| ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | NCT01001377 | Metastatic Colo... | Cetuximab Panitumumab | 18 Years - | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
